GEN-001

Genprex has entered into an exclusive patent license agreement with UTHealth Houston for its REQORSA gene therapy to treat glioblastoma, expanding beyond its established lung cancer applications.

Genprex's Acclaim-3 trial, evaluating Reqorsa with Tecentriq for extensive stage small cell lung cancer (ES-SCLC), has advanced to Phase 2.

Kiromic BioPharma's Deltacel T-cell therapy demonstrates disease stabilization in NSCLC patients, showing potential in advanced solid tumor treatment.

Genprex presented positive preclinical data for Reqorsa, a gene therapy targeting Ras inhibitor-resistant lung cancer, mesothelioma, and glioblastoma, showing increased TUSC2 uptake in tumor cells.

Genprex has entered a sponsored research agreement with the University of Michigan to study Reqorsa® gene therapy combined with ALK-inhibitors for ALK+ lung cancer.